Study defines small-cell lung cancer subtypes and distinct therapeutic
vulnerabilities for each type
Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type in a study published today in Cancer Cell.
SCLC is known for rapid, aggressive growth and resistance to treatment, which leads to poor outcomes. While recent...
An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University...
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas...
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
UroGen’s approach involves the local delivery of potent immunomodulators (UGN-201, a TLR 7/8 agonist and UGN-301, an...
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The...
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization...
Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is...
Following receipt of the Pfizer COVID-19 vaccine on Monday morning, MD Anderson’s Pharmacy, Infection Control, Employee Health and clinical...
Mariana Chavez Mac Gregor, M.D., M.Sc., associate professor in Health Services Research with a joint appointment in Breast Medical Oncology...